Chronic inflammation and immunological dysregulation contribute to the progression of BPH, and in vitro research has shown that the administration of dihydrotestosterone, which inhibits CD4 T cells’ production of pro-inflammatory cytokines, has an immunomodulatory effect (55). Here, CD4 is linked to benign prostatic hyperplasia.